Adicet Bio, Inc. (ACET)

Market Cap	80.21M
Revenue (ttm)	n/a
Net Income (ttm)	-117.88M
Shares Out	82.40M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	298,736
Open	1.020
Previous Close	1.000
Day's Range	0.966 - 1.030
52-Week Range	0.810 - 2.610
Beta	1.64
Analysts	Buy
Price Target	5.67 (+482.49%)
Earnings Date	Mar 18, 2025

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET
• Website: https://www.adicetbio.com

Analyst Forecast

According to 5 analysts, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $5.67, which is an increase of 482.49% from the latest price.

Price Target

$5.67

(482.49% upside)

Analyst Consensus: Buy